Table 1.
Demographic details of the patients with AISC, PSC, UC and CD.
| AISC | AISC + IBD | PSC | PSC + IBD | UC | Crohn's disease | |
|---|---|---|---|---|---|---|
| Number | 5 | 18 | 6 | 16 | 55 | 55 |
| Age at diagnosis (years)⁎ | 10.8 ± 1.7 | 12.3 ± 1.0 | 41.7 ± 5.9 | 30.9 ± 2.9 | 38.6 ± 17.1 | 33.2 ± 15.9 |
| Age at study (years)⁎ | 18.0 ± 0.8 | 19.4 ± 0.6 | 47.5 ± 5.6 | 42.9 ± 3.7 | 44.6 ± 18.6 | 38.7 ± 17.2 |
| Duration of colitis⁎ | 4.5 ± 0.9 | 8.2 ± 1.7 | ||||
| Treatment | ||||||
| Prednisolone (2.5–10 mg/day) | 3/5 (60%) | 14/18 (78%) | 5/6 (83%) | 11/16 (69%) | 0 | 1/55 (1.8%) |
| Azathioprine (25–125 mg) | 3/5 (60%) | 16/18 (89%) | 4/6 (67%) | 14/16 (88%) | 11/55 (20%)⁎⁎ | 16/55 (29%)⁎⁎ |
| Ursodeoxycholic acid (UDCA) | 4/5 (80%) | 17/18 (94%) | 6/6 (100%) | 15/16 (94%) | 0 | 0 |
| Tacrolimus | 1/5 (20%) | 5/18 (28%) | 0/6 (0%) | 9/16 (56%) | 0 | 0 |
| Mycophenolate | 0/5 (0%) | 1/18 (6%) | 0/6 (0%) | 3/16 (19%) | 0 | 0 |
| Mesalazine | 0/5 (0%) | 15/18 (83%) | 0/6 (0%) | 13/16 (81%) | 49/55 (89%) | 32/55 (58%) |
| Faecal calprotectin (microg/g)⁎ | 34.4 ± 8.3 | 588 ± 549 | 39.7 ± 8.4 | 428 ± 351 | 501 ± 656 | 476 ± 571 |
AISC = Autoimmune sclerosing cholangitis.
PSC = Primary sclerosing cholangitis.
UC = Ulcerative colitis.
UDCA = Ursodeoxycholic acid.
⁎
Mean ± SD.
⁎⁎
Azathioprine dose in UC and Crohn's disease ranged from 100 to 225 mg (2–21/2 mg per kg bodyweight).